1.Explore of influence factors on the prognosis of patients with hemorrhagic transformation after cerebral infarction
Jialan SUN ; Yi FU ; Jian SUN
Journal of Clinical Neurology 1995;0(04):-
0.05),but there were the significant difference of prognosis in point and sheet bleeding groups,internal carotid artery system group with hemorrhage,multiple site bleeding group compared with that of cerebral infarction group(all P0.05).Conclusion The correlation factors of impact on HT after cerebral infarction mainly have the volume of blood and bleeding part.
2.Design and synthesis of imidazo-fused heterocycles derivatives and their anti-tumor activity against breast cancer in mice.
Jin ZHOU ; Bohong LIAO ; Yinggui DENG ; Xiaowen GUO ; Jialan ZHAO ; Jie SUN ; Zhibo ZHU
Journal of Southern Medical University 2018;38(9):1052-1060
OBJECTIVETo synthesize compounds based on imidazo-fused heterocycles and evaluate their anti-tumor activity against breast cancer.
METHODSThe compounds 1a-1e, 2a and 2b were synthesized by aerobic copper-catalyzed halocyclization of methyl N-heteroaromatics with aliphatic amines; 3a and 3b were generated by sonogashira reaction and Suzuki reaction, respectively; the compounds 4a-4c were obtained by Buchwald-Hartwig reaction of the corresponding amines and 1e. The effects of these compounds against breast cancer cells and their nephrotoxicity were determined using MTT assay. Annexin VFITC/PI apoptosis detection kit was used to assess the apoptosis-inducing effects of these compounds in breast cancer cells. With normal saline as the control, the safety and anti-tumor activity of the compound 2a (daily dose of 10 mg/kg for 14 days) was tested in a mouse model bearing human breast cancer xenografts.
RESULTSThe compounds 2a, 4a, 4b and 4c all showed obvious anti-tumor activities. Among these compounds, 2a showed the most potent anti-tumor effect against breast cancer cells with an IC of 9.77 ± 2.32 μmol/L, similar to that of cisplatin (IC=8.96 ± 2.35 μmol/L); 2a also showed a slightly lower nephrotoxicity than cisplatin, and their CC was 10.79±0.87 μmol/L and 8.45±0.68 μmol/L, respectively. 2a obviously promoted apoptosis of breast cancer cells and caused a moderate suppression of the breast cancer growth in the tumor-bearing mouse models without producing serious adverse effects.
CONCLUSIONSFour compounds synthesized based on imidazo-fused heterocycles have anti-tumor activities against breast cancer. The compound 2a is capable of dose-dependently promoting apoptosis of breast cancer cells and has a good safety and a moderate efficacy for suppressing tumor growth in mouse models bearing human breast cancer xenografts.